Clinical Trial Update: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. [Phase 1]

View source ↗

Summary

This is a Phase 1 dose-escalation and expansion study evaluating intratumoral ONM-501 alone and in combination with cemiplimab in patients with advanced solid t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Cervical Cancer
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma
• Triple-negative Breast Cancer
• Uveal Melanoma

Drugs mentioned

• Cemiplimab (cemiplimab)
• ONM-501 (ONM-501)

Snippet

Sponsor: OncoNano Medicine, Inc. | Conditions: Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma | Phase 1 | Status: RECRUITING